vs
CareTrust REIT, Inc.（CTRE）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
CareTrust REIT, Inc.的季度营收约是再鼎医药的1.1倍（$134.9M vs $127.1M），CareTrust REIT, Inc.同比增速更快（55.1% vs 17.1%），过去两年CareTrust REIT, Inc.的营收复合增速更高（46.2% vs 20.8%）
本公司是一家英国房地产投资企业，专注于医疗类不动产投资，持有规模庞大的养老护理院资产组合。公司采用房地产投资信托（REIT）架构，在伦敦证券交易所上市，是富时250指数成分股。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CTRE vs ZLAB — 直观对比
营收规模更大
CTRE
是对方的1.1倍
$127.1M
营收增速更快
CTRE
高出38.0%
17.1%
两年增速更快
CTRE
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $134.9M | $127.1M |
| 净利润 | $111.3M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 82.5% | — |
| 营收同比 | 55.1% | 17.1% |
| 净利润同比 | 113.5% | — |
| 每股收益（稀释后） | $0.52 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTREZLAB
| Q4 25 | $134.9M | $127.1M | ||
| Q3 25 | $132.4M | $115.4M | ||
| Q2 25 | $112.5M | $109.1M | ||
| Q1 25 | $96.6M | $105.7M | ||
| Q4 24 | $86.9M | $108.5M | ||
| Q3 24 | $77.4M | $101.8M | ||
| Q2 24 | $68.9M | $100.1M | ||
| Q1 24 | $63.1M | $87.1M |
净利润CTREZLAB
| Q4 25 | $111.3M | — | ||
| Q3 25 | $74.9M | $-36.0M | ||
| Q2 25 | $68.5M | $-40.7M | ||
| Q1 25 | $65.8M | $-48.4M | ||
| Q4 24 | $52.1M | — | ||
| Q3 24 | $33.4M | $-41.7M | ||
| Q2 24 | $10.8M | $-80.3M | ||
| Q1 24 | $28.7M | $-53.5M |
毛利率CTREZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CTREZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | 58.1% | -42.3% | ||
| Q2 25 | 61.3% | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | 43.0% | -66.6% | ||
| Q2 24 | 15.1% | -76.0% | ||
| Q1 24 | — | -80.7% |
净利率CTREZLAB
| Q4 25 | 82.5% | — | ||
| Q3 25 | 56.6% | -31.2% | ||
| Q2 25 | 60.9% | -37.3% | ||
| Q1 25 | 68.1% | -45.8% | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 43.2% | -40.9% | ||
| Q2 24 | 15.6% | -80.2% | ||
| Q1 24 | 45.6% | -61.4% |
每股收益（稀释后）CTREZLAB
| Q4 25 | $0.52 | $-0.05 | ||
| Q3 25 | $0.35 | $-0.03 | ||
| Q2 25 | $0.35 | $-0.04 | ||
| Q1 25 | $0.35 | $-0.04 | ||
| Q4 24 | $0.30 | $-0.09 | ||
| Q3 24 | $0.21 | $-0.04 | ||
| Q2 24 | $0.07 | $-0.08 | ||
| Q1 24 | $0.22 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.0M | $689.6M |
| 总债务越低越好 | $894.2M | — |
| 股东权益账面价值 | $4.0B | $715.5M |
| 总资产 | $5.1B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.22× | — |
8季度趋势，按日历期对齐
现金及短期投资CTREZLAB
| Q4 25 | $198.0M | $689.6M | ||
| Q3 25 | $712.5M | $717.2M | ||
| Q2 25 | $306.1M | $732.2M | ||
| Q1 25 | $26.5M | $757.3M | ||
| Q4 24 | $213.8M | $779.7M | ||
| Q3 24 | $377.1M | $616.1M | ||
| Q2 24 | $495.1M | $630.0M | ||
| Q1 24 | $451.2M | $650.8M |
总债务CTREZLAB
| Q4 25 | $894.2M | — | ||
| Q3 25 | $893.8M | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $822.1M | — | ||
| Q4 24 | $396.9M | — | ||
| Q3 24 | $396.7M | — | ||
| Q2 24 | $671.1M | — | ||
| Q1 24 | $595.9M | — |
股东权益CTREZLAB
| Q4 25 | $4.0B | $715.5M | ||
| Q3 25 | $4.0B | $759.9M | ||
| Q2 25 | $3.3B | $791.7M | ||
| Q1 25 | $2.9B | $810.8M | ||
| Q4 24 | $2.9B | $840.9M | ||
| Q3 24 | $2.4B | $667.7M | ||
| Q2 24 | $1.9B | $704.2M | ||
| Q1 24 | $1.7B | $762.2M |
总资产CTREZLAB
| Q4 25 | $5.1B | $1.2B | ||
| Q3 25 | $5.1B | $1.2B | ||
| Q2 25 | $4.7B | $1.2B | ||
| Q1 25 | $3.9B | $1.2B | ||
| Q4 24 | $3.4B | $1.2B | ||
| Q3 24 | $2.9B | $985.3M | ||
| Q2 24 | $2.7B | $987.4M | ||
| Q1 24 | $2.3B | $988.4M |
负债/权益比CTREZLAB
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $394.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 3.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CTREZLAB
| Q4 25 | $394.0M | $-26.0M | ||
| Q3 25 | $100.9M | $-32.0M | ||
| Q2 25 | $100.8M | $-31.0M | ||
| Q1 25 | $71.4M | $-61.7M | ||
| Q4 24 | $244.3M | $-55.8M | ||
| Q3 24 | $67.2M | $-26.8M | ||
| Q2 24 | $53.0M | $-42.2M | ||
| Q1 24 | $48.8M | $-90.1M |
自由现金流CTREZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率CTREZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度CTREZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率CTREZLAB
| Q4 25 | 3.54× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTRE
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
